In Phase C, contributors will receive ABBV-744 and oral navitoclax. In Phase D, individuals will receive ABBV-744 and ruxolitinib. Participants will receive treatment right up until sickness progression or the contributors are unable to tolerate the study drugs. Overall, our latest work highlights the potential utilization of ARV-825 in combination https://josefae333pak5.dailyblogzz.com/profile